Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo‐controlled phase 3 trial

Tofacitinib is an oral Janus kinase inhibitor. These post‐hoc analyses assessed tofacitinib efficacy and safety in Japanese patients with psoriasis enrolled in a 52‐week global phase 3 study. Patients received tofacitinib 5 mg, tofacitinib 10 mg or placebo twice daily (b.i.d.); placebo‐treated patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Masatoshi, Nishigori, Chikako, Torii, Hideshi, Ihn, Hironobu, Ito, Kei, Nagaoka, Makoto, Isogawa, Naoki, Kawaguchi, Isao, Tomochika, Yukiko, Kobayashi, Mihoko, Tallman, Anna M., Papp, Kim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697670/
https://www.ncbi.nlm.nih.gov/pubmed/28714180
http://dx.doi.org/10.1111/1346-8138.13956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697670/
https://www.ncbi.nlm.nih.gov/pubmed/28714180
http://dx.doi.org/10.1111/1346-8138.13956

Ejemplares similares